Pfizer pays $35m for Rapamune settlement
This article was originally published in Scrip
Executive Summary
Pfizer has reached a $35m settlement with 41 US states and Washington, DC arising from alleged improper marketing and promotion of the immunosuppressant Rapamune (sirolimus).